https://www.mdpi.com/1422-0067/27/8/3634
chatGPT(5.5paid):
Summary
This is a 2026 review paper arguing that the healthspan benefits of the Mediterranean diet are not due to one “active ingredient”, but to a network of interacting plant polyphenols and phytochemicals. The paper uses a proprietary supplement, DailyColors™, as a model of a Mediterranean-diet-derived polyphenol blend. It contains extracts/powders from 16 plant sources including grape, ginger, elderberry, rosemary, blueberry, pomegranate, olive, onion, tomato, beet, kale and others. The authors describe it as a controlled-dose way to study Mediterranean diet bioactives without the variability of whole-diet adherence.
The central mechanistic claim is that Mediterranean diet polyphenols act across several aging-relevant pathways, including NAD⁺ metabolism, CD38/CD39/CD73 activity, inflammation, NF-κB signalling, oxidative stress, mitochondrial/metabolic function, cognition, extracellular vesicle biology, and epigenetic methylation patterns. The paper particularly emphasizes CD38 inhibition, because CD38 rises with age and contributes to NAD⁺ decline. In vitro, DailyColors™ reportedly inhibited CD38, CDK5/p25, Cathepsin S, arginases, JAK signalling, BACE1 and acetylcholinesterase, although several of these findings are described as unpublished.
The preclinical section reports that the supplement reduced LPS-induced IL-6, TNF-α and PGE2 in primary human monocytes, suppressed NF-κB at higher doses, inhibited ROS production in macrophages, altered adipokine secretion in 3T3-L1 adipocyte models, and improved movement/healthspan markers in C. elegans. Some effects were not uniformly anti-inflammatory: IL-8, MCP-1 and IL-1β increased in the monocyte assay, which is important and somewhat underplayed by the authors.
The human evidence comes mainly from two trials. One small crossover study in 30 adults with BMI >25 used 150 mg/day for one week and reported that CD38 rose during placebo but not active treatment, with a trend toward lower 4-HNE, followed by an open-label extension showing methylation changes at cg13108341. A second 60-day randomized trial in 150 UK adults aged 50+ with BMI ≥25 tested 750 mg/day and 2000 mg/day and reported improved cognitive performance, reaction time and physical fitness measures, with proteomic shifts in immune, inflammatory, vesicle transport and HDL-related pathways.
The paper concludes that the Mediterranean diet, and a concentrated polyphenol blend meant to mimic aspects of it, may support healthy aging through multi-compound, multi-pathway synergy rather than through a single molecule or pathway.
Claimed novelty
The novelty is not the claim that the Mediterranean diet is beneficial; that is already well established. The novel aspect is the attempt to translate the Mediterranean diet into a network-biology supplement model and then map its effects across enzyme assays, cell systems, C. elegans, proteomics, cognition and methylation.
More specifically, the paper’s novelty lies in:
-
A “Mediterranean diet in a capsule” framing: using a standardized 16-plant blend to reduce dietary variability and study mechanisms under controlled dosing.
-
Network biology rather than single-polyphenol reductionism: the authors explicitly argue that single compounds cannot reproduce the systemic effects of a Mediterranean dietary pattern.
-
CD38/NAD⁺ as a central aging node: the review links Mediterranean polyphenols to CD38 inhibition, NAD⁺ preservation, inflammaging and immune regulation.
-
Multi-omics readouts: the clinical studies include proteomic and epigenetic signals rather than only conventional biomarkers or symptom outcomes.
-
Integration of cognition, metabolism, inflammation and aging biomarkers into one proposed mechanistic framework.
Critique
The paper is interesting but reads partly like a scientific review and partly like a product dossier. DailyColors™ is not merely used as an example; it becomes the main object of the review. That makes the argument more focused, but also creates a risk that the Mediterranean diet is being rhetorically used to support a specific proprietary formulation.
A major limitation is the heavy reliance on unpublished preclinical data. Several important mechanistic claims — including effects on CD39/CD73, JAK1/2/3, BACE1, Keap1–Nrf2, ROS assays, acetylcholinesterase, fibroblast aging markers and insulin sensitivity — are described as unpublished. That makes them difficult to evaluate independently.
The clinical evidence is suggestive but not definitive. The first trial is very small and short, with only one week of blinded supplementation and a one-month open-label extension. The methylation result at a single CpG site is intriguing but should not be treated as strong evidence of age reversal. The second trial is larger, but 60 days remains short for claims about healthspan, aging or disease prevention.
The authors sometimes move too quickly from biomarker modulation to healthspan interpretation. For example, inhibition of CD38 or changes in HDL-associated proteins are biologically plausible, but they do not by themselves prove improved aging rate, reduced disease incidence or longer healthspan. Similarly, improved C. elegans movement is useful preclinical evidence, but it is not equivalent to human longevity evidence.
There is also a mechanistic ambiguity around “synergy”. The paper repeatedly invokes synergy, but it is not clear that true synergy was formally demonstrated. To prove synergy, one would need systematic comparison of the blend against individual components and mathematically defined additive/null models. Much of the evidence instead shows that a complex mixture has effects, which is not the same thing as proving synergistic interaction.
The conflict-of-interest section says all authors are employed by KGK Science, and KGK previously provided regulatory assistance to DailyColors™, though the authors state KGK did not conduct the DailyColors™ clinical trial and declare no other competing interests. That is not necessarily disqualifying, but it does mean the paper should be read with attention to promotional bias.
Overall assessment
The paper is a useful hypothesis-generating review and a reasonably coherent systems-biology argument for why diverse Mediterranean plant polyphenols may act through overlapping aging-related pathways. Its strongest contribution is integrating Mediterranean diet biology with CD38/NAD⁺, inflammation, proteomics and epigenetic biomarkers.
Its weakest point is evidential overreach. The data support the idea that the blend is biologically active and may have short-term effects on inflammatory, cognitive and omics markers. They do not yet establish that DailyColors™ reproduces the full Mediterranean diet, reverses aging, or improves long-term healthspan. A stronger next step would be a larger, longer, independently run RCT with predefined primary endpoints, direct NAD⁺/CD38 measures, dietary controls, and comparison arms including Mediterranean diet, supplement, and placebo.